Investor Presentation Full Year 2021
25
Investor presentation
Full year 2021
Sales growth of 14% at CER, driven by all therapy areas and in
particular the portfolio of GLP-1 treatments
Novo Nordisk®
Novo Nordisk reported quarterly sales
DKK
billion
50
by therapy
Reported sales
CAGR1: 8.0%
Reported sales for the full
year 2021
Reported sales and growth breakdown for
the full year 2021
Rare
endocrine
Therapy
40
40
Rare disorders
Other
Biopharm
Sales
(mDKK)
Growth
Share of
growth
Total GLP-12
53,597
32%
76%
Long-acting insulin³
18,064
0%
0%
blood
disorders
1%
Premix insulin4
11,203
4%
2%
(1.4%)¹
5%
Fast-acting insulin5
17,687
(1%)
(1%)
30
Obesity
7%
Human insulin
2.5%1
9,052
4%
2%
care
6%
Total insulin
56,006
1%
4%
2.7%1
Other Diabetes care
3,594
(10%)
(2%)
20
9.2%¹
Total Diabetes care
Obesity care7
113,197
13%
78%
8,400
55%
18%
10
Diabetes and Obesity care
121,597
15%
95%
80%
Rare blood disorders
10,217
9%
5%
0
Q4
Other biopharm
2011
Rare endocrine disorders
Rare blood disorders
Q4
2021
Diabetes and Obesity care
Sales of DKK 140.8 billion (11%)
Diabetes care
Rare endocrine disorders⁹
Other Biopharm 10
Biopharm
7,303
(2%)
(1%)
1,683
8%
1%
19,203
4%
5%
Total
140,800
14%
100%
1 CAGR for 10-year period; 2 Comprises Victoza®, Ozempic®, Rybelsus®; 3 Comprises TresibaⓇ, XultophyⓇ and Levemir®; 4 Comprises RyzodegⓇ and NovoMixⓇ; 5 Comprises FiaspⓇ and NovoRapidⓇ; 6 Primarily NovonormⓇ, needles and GlucaGen® HypoKitⓇ;
7 Comprises SaxendaⓇ and Wegovy® 8 Comprises NovoSevenⓇ, Novo Eight®, NovoThirteen®, Refixia®, and EsperoctⓇ: 9 Comprises Norditropin and Macrilen TM; 10 Primarily Vagifem® and ActivelleⓇ
Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange rate, except for total sales growth of 11%; Refixia® and NovoThirteenⓇ are launched as RebinynⓇ and TRETTENⓇ, respectively, in North America.View entire presentation